Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma

van Haarst, J.M.W.; Baas, P.; Manegold, C.; Schouwink, J.H.; Burgers, J.A.; de Bruin, H.G.; Mooi, W.J.; van Klaveren, R.J.; de Jonge, M.J.A.; van Meerbeeck, J.P.

doi:10.1038/SJ.BJC.6600118

Title

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma

Author

van Haarst, J.M.W.

Baas, P.

Manegold, C.

Schouwink, J.H.

Burgers, J.A.

de Bruin, H.G.

Mooi, W.J.

van Klaveren, R.J.

de Jonge, M.J.A.

van Meerbeeck, J.P.

Abstract

Malignant pleural mesothelioma is a notoriously chemoresistant tumour. However, a recent single institution study showed an impressive activity of gemcitabine and cisplatin. Our aim is to investigate the efficacy and toxicity of a gemcitabine and cisplatin combination in selected and chemo-naive patients with histologically proven malignant pleural mesothelioma. Method: Gemcitabine 1250 mg m(-2) was administered on day 1 and day 8 and cisplatin 80 mg m(-2) was administered on day 1 in a 3-week cycle with a maximum of six cycles. Response and toxicity evaluations were performed according to WHO and NCIC-CTC criteria. Pathology and radiology were centrally reviewed. Results show that in 25 evaluable patients, four PR were observed (ORR 16%, 95% CI 1-31%). Responses of seven patients were unevaluable. No unexpected toxicity occurred. Time to progression was 6 months (5-7 months) with a median survival from registration of 9.6 months (95% CI 8-12 months). In conclusion this trial excludes with 90% power a response rate of greater than 30% in patients with malignant pleural mesothelioma using a combination of gemcitabine and cisplatin at the proposed dose and schedule.

Language

English

Source (journal)

The British journal of cancer. - London

Publication

London : 2002

ISSN

0007-0920

DOI

10.1038/SJ.BJC.6600118

10.1038/SJ/BJC/6600118

Volume/pages